Medicine and Dentistry
Randomized Controlled Trial
100%
Cancer Therapy
83%
Arabinoxylan
50%
Therapeutic Procedure
50%
Immune System
33%
Complementary Therapy
33%
Immunomodulating Agent
33%
Malignant Neoplasm
33%
Neoplasm
16%
In Vitro
16%
Cell Activity
16%
Surgery
16%
Adverse Event
16%
Radiation Therapy
16%
Combination Therapy
16%
Recurrent Disease
16%
Drug Resistance
16%
Tumor Progression
16%
Survival Rate
16%
Side Effect
16%
Drug Toxicity
16%
Natural Killer Cell
16%
Base
16%
Enalapril Maleate
16%
Cells
16%
Fighting
16%
Pharmacology, Toxicology and Pharmaceutical Science
Arabinoxylan
50%
Clinical Study
33%
Intervention Study
33%
Chemotherapy
33%
Malignant Neoplasm
33%
Clinical Trial
33%
Immunomodulating Agent
33%
Adverse Event
16%
Antiinfective Agent
16%
Neoplasm
16%
Tumor Growth
16%
Side Effect
16%
Survival Rate
16%
Drug Toxicity
16%
Drug Resistance
16%
Recurrent Disease
16%
Enalapril Maleate
16%
Plant
16%
Base
16%